PMID- 26951899
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20171213
IS  - 1724-6032 (Electronic)
IS  - 1129-7298 (Linking)
VI  - 17 Suppl 1
DP  - 2016 Mar
TI  - Permanent arteriovenous fistula or catheter dialysis for heart failure patients.
PG  - S23-9
LID - 10.5301/jva.5000511 [doi]
AB  - Heart failure (HF) is the most frequent cardiovascular disease associated with 
      chronic kidney disease and represents a high risk for cardiovascular mortality in 
      incident hemodialysis (HD) patients. This risk is especially high during the 
      arteriovenous fistula (AVF) maturation period due to the marked hemodynamic 
      changes related to the large increase in the blood flow and also within the first 
      120 days after HD inception because in this period the highest mortality rate 
      occurs. When planning the vascular access for each incident HF patient, the risk 
      of aggravating HF after AVF creation must be evaluated carefully alongside the 
      risk of catheter-related complications, but avoiding a non-selective 'catheter 
      first' approach for all these patients. HF patients classified within the New 
      York Heart Association (NYHA) Class I-II and the American College of 
      Cardiology/American Heart Association (ACC/AHA) Stage A-B could initiate HD 
      through a distal arm AVF. High-flow brachial artery-based AVF creation must be 
      avoided because it displays the highest risk of worsening the cardiac function. 
      The decision for AVF creation or tunneled central catheter placement in HF 
      patients classified within the NYHA Class III and the ACC/AHA Stage C must have 
      been individualized according the degree of systolic and/or diastolic 
      dysfunction. HF patients with significant reduction in systolic function 
      (ejection fraction lower than 30%) or classified within the NYHA Class IV and the 
      ACC/AHA Stage D, are candidates for tunneled catheter placement to start HD 
      treatment.
FAU - Roca-Tey, Ramon
AU  - Roca-Tey R
AD  - Department of Nephrology, Hospital de Mollet, Barcelona - Spain.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160306
PL  - United States
TA  - J Vasc Access
JT  - The journal of vascular access
JID - 100940729
SB  - IM
MH  - *Arteriovenous Shunt, Surgical/adverse effects/mortality
MH  - *Catheterization, Central Venous/adverse effects/instrumentation/mortality
MH  - Catheters, Indwelling
MH  - Central Venous Catheters
MH  - Heart Failure/*complications/mortality/physiopathology
MH  - Hemodynamics
MH  - Humans
MH  - Kidney Failure, Chronic/complications/mortality/physiopathology/*therapy
MH  - Regional Blood Flow
MH  - *Renal Dialysis/adverse effects/mortality
MH  - Risk Factors
MH  - Treatment Outcome
EDAT- 2016/03/10 06:00
MHDA- 2016/12/15 06:00
CRDT- 2016/03/09 06:00
PHST- 2015/12/08 00:00 [accepted]
PHST- 2016/03/09 06:00 [entrez]
PHST- 2016/03/10 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - ECEE26C0-A1BC-4FF9-BC9D-543F309A166F [pii]
AID - 10.5301/jva.5000511 [doi]
PST - ppublish
SO  - J Vasc Access. 2016 Mar;17 Suppl 1:S23-9. doi: 10.5301/jva.5000511. Epub 2016 Mar 
      6.